Related Experiment Videos
Immunotherapy of multiple myeloma
1Department of Experimental Transplantation and Immunology, Medicine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Seminars in Hematology
|August 7, 2001
Summary
Immunotherapy offers new hope for multiple myeloma (MM) patients when chemotherapy fails. Research explores antibody, vaccination, and T-cell strategies, including dendritic cell vaccines and adoptive T-cell immunotherapy, to combat this lethal disease.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Chemotherapy resistance in multiple myeloma (MM) necessitates novel treatment strategies.
- Advances in tumor immunology and MM biology highlight the potential of immunotherapy.
- Existing immunotherapies show promise but require further refinement for efficacy.
Purpose of the Study:
- To review advancements in multiple myeloma immunotherapy since 1998.
- To explore different immunotherapy approaches: passive antibody, active vaccination, and adoptive T-cell therapy.
- To discuss the potential of tumor-specific antigens and dendritic cell-based vaccines.
Main Methods:
- Review of published data on multiple myeloma immunotherapy from 1998 onwards.
- Analysis of clinical trials involving monoclonal antibodies (mAbs).
- Evaluation of strategies utilizing immunoglobulin idiotype as a tumor-specific antigen.
- Assessment of dendritic cell-based vaccines and adoptive T-cell transfer.
Main Results:
- Early anti-CD20 mAb trials show limited success but suggest potential in specific patient subgroups.
- Immunoglobulin idiotype is a viable target for active specific immunization (vaccination).
- Ex vivo generation of dendritic cell vaccines and MM-specific cytotoxic T lymphocytes (CTLs) is feasible.
Conclusions:
- Immunotherapy holds significant promise for treating multiple myeloma.
- Customized vaccines using dendritic cells and adoptive T-cell transfer represent promising therapeutic avenues.
- Continued research into tumor immunology and novel antigen targeting is crucial for improving MM treatment outcomes.